keyword
MENU ▼
Read by QxMD icon Read
search

Prostate cancer radiotherapy

keyword
https://www.readbyqxmd.com/read/28209912/detection-efficacy-of-hybrid-68-ga-psma-ligand-pet-ct-in-prostate-cancer-patients-with-biochemical-recurrence-after-primary-radiation-therapy-defined-by-phoenix-criteria
#1
Ingo Einspieler, Isabel Rauscher, Charlotte Düwel, Markus Krönke, Christoph Rischpler, Gregor Habl, Sabrina Dewes, Armin Ott, Hans-Jürgen Wester, Markus Schwaiger, Tobias Maurer, Matthias Eiber
The aim of this retrospective study was to evaluate the detection rate of Glu-NH-CO-NH-Lys-(Ahx)-[(68)Ga(HBED-CC)] ((68)Ga-PSMA ligand) positron emission tomography/computed tomography (PET/CT) in patients with biochemical recurrent prostate cancer (PC) defined by Phoenix criteria after external beam radiotherapy (EBRT) or brachytherapy as primary treatment. Methods: 118 patients were finally eligible for this retrospective analysis with a median prostate-specific antigen (PSA) of 6.4 ng/mL (range: 2.2-158...
February 16, 2017: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
https://www.readbyqxmd.com/read/28208703/androgen-receptor-signaling-in-salivary-gland-cancer
#2
REVIEW
Martin G Dalin, Philip A Watson, Alan L Ho, Luc G T Morris
Salivary gland cancers comprise a small subset of human malignancies, and are classified into multiple subtypes that exhibit diverse histology, molecular biology and clinical presentation. Local disease is potentially curable with surgery, which may be combined with adjuvant radiotherapy. However, metastatic or unresectable tumors rarely respond to chemotherapy and carry a poorer prognosis. Recent molecular studies have shown evidence of androgen receptor signaling in several types of salivary gland cancer, mainly salivary duct carcinoma...
February 8, 2017: Cancers
https://www.readbyqxmd.com/read/28208523/re-patient-reported-outcomes-after-monitoring-surgery-or-radiotherapy-for-prostate-cancer
#3
David F Penson
No abstract text is available yet for this article.
March 2017: Journal of Urology
https://www.readbyqxmd.com/read/28206966/impact-of-dna-repair-gene-polymorphisms-on-the-risk-of-biochemical-recurrence-after-radiotherapy-and-overall-survival-in-prostate-cancer
#4
Chiara Zanusso, Roberto Bortolus, Eva Dreussi, Jerry Polesel, Marcella Montico, Erika Cecchin, Sara Gagno, Flavio Rizzolio, Mauro Arcicasa, Giacomo Novara, Giuseppe Toffoli
The identification of biomarkers of biochemical recurrence (BCR) in prostate cancer (PCa) patients undergoing radiotherapy (RT) represents an unanswered clinical issue. The primary aim of this study was the definition of new genetic prognostic biomarkers in DNA repair genes (DRGs), considering both BCR and overall survival (OS) as clinical end-points. The secondary aim was to explore the potential clinical impact of these genetic variants with the decision curve analysis (DCA) and the sensitivity analysis.We analyzed 22 germline polymorphisms in 14 DRGs on 542 Caucasian PCa patients treated with RT as primary therapy...
February 11, 2017: Oncotarget
https://www.readbyqxmd.com/read/28202212/long-term-patient-reported-urinary-function-following-external-beam-radiotherapy-for-prostate-cancer
#5
S Chin, A J Hayden, V Gebski, S Cross, S L Turner
INTRODUCTION: This study reports long-term patient reported urinary function and urinary-related quality of life (uQoL) after external beam radiotherapy (EBRT) for localized prostate cancer. METHODS: 574 men underwent definitive prostate EBRT to 70-78 Gy±androgen deprivation therapy between 2000 and 2009. The median follow-up from EBRT was 44 months. Patients were evaluated at baseline (pre-EBRT) and at intervals post-treatment using the International Prostate Symptom Score (IPSS) instrument...
February 12, 2017: Clinical Oncology: a Journal of the Royal College of Radiologists
https://www.readbyqxmd.com/read/28197671/-rectal-perforation-a%C3%A2-rare-complication-following-radiotherapy
#6
M Binnebösel, A Lambertz, C D Klink, U P Neumann
BACKGROUND: Radiotherapy in the treatment of prostate cancer is well established. Intestinal complications following radiotherapy are divided into acute and chronic toxicity. Chronic complications like perforation and fistula formation to the rectum are rare and difficult to treat. MATERIALS AND METHODS: In case of chronic radiotherapy complications and particularly chronic fistula formation to the rectum, evidence is low. Therefore, an overview of the available literature of surgical therapy strategies is given...
February 14, 2017: Der Urologe. Ausg. A
https://www.readbyqxmd.com/read/28191295/small-cell-carcinoma-of-the-prostate-in-an-elderly-patient-a-case-report-and-review-of-the-literature
#7
Dale Alan Whitaker, Daniel H Miller, Niveditha Jagadesh, Gerald W Strong, Lauren Hintenlang, William B Schenk, Gregory A Broderick, Katherine S Tzou, Steven J Buskirk
Prostate cancer is the most common malignancy of men in the United States. Small-cell carcinoma (SCC), which typically presents as an aggressive lung malignancy, is a rare diagnosis within the setting of prostate cancer pathology. Due to its limited prevalence, little information regarding the treatment and prognosis of this disease in large populations is available. To date our current knowledge base is largely limited to case reports and retrospective case reviews. The mainstay of treatment for this particular histology most often involves a multimodality approach utilizing chemotherapy in conjunction with radiation therapy, androgen deprivation therapy, or prostatectomy...
November 17, 2016: Rare Tumors
https://www.readbyqxmd.com/read/28190764/bicalutamide-with-radiotherapy-for-prostate-cancer
#8
Vicki Brower
No abstract text is available yet for this article.
February 9, 2017: Lancet Oncology
https://www.readbyqxmd.com/read/28190704/high-risk-prostate-cancer-and-radiotherapy-the-past-and-the-future-a-benchmark-for-a-new-mixed-beam-radiotherapy-approach
#9
Giulia Marvaso, Barbara A Jereczek-Fossa, Giulia Riva, Camilla Bassi, Cristiana Fodor, Delia Ciardo, Raffaella Cambria, Floriana Pansini, Dario Zerini, Paolo De Marco, Federica Cattani, Ottavio De Cobelli, Roberto Orecchia
BACKGROUND: The prognosis for patients with high-risk prostate cancer is poor. No consensus exists on the most effective treatment. The aim of this retrospective study was to identify the biochemical progression-free survival and the toxicity profile of patients with localized high-risk prostate cancer treated with external beam radiation therapy. These results will constitute a benchmark for a prospective "mixed beam" trial: a boost with carbon ions followed by a pelvic photon intensity-modulated radiotherapy (NCT02672449 [clinicaltrials...
January 18, 2017: Clinical Genitourinary Cancer
https://www.readbyqxmd.com/read/28190638/long-term-toxicity-and-health-related-quality-of-life-after-single-fraction-high-dose-rate-brachytherapy-boost-and-hypofractionated-external-beam-radiotherapy-for-intermediate-risk-prostate-cancer
#10
N Shahid, A Loblaw, H T Chung, P Cheung, E Szumacher, C Danjoux, R Sankreacha, L Zhang, A Deabreu, A Mamedov, G Morton
AIMS: To report health-related quality of life (HRQOL) and toxicity in prostate cancer patients treated with single-fraction high dose rate (HDR) brachytherapy boost and external beam radiotherapy (EBRT). MATERIALS AND METHODS: Patients with intermediate-risk prostate cancer were accrued to a phase II clinical trial of 15 Gy HDR boost and EBRT to a dose of 37.5 Gy in 15 fractions. HRQOL (Expanded Prostate Cancer Index Composite [EPIC]), urinary symptoms (International Prostate Symptom Score [IPSS]), erectile function (International Index of Erectile Function [IIEF]) and toxicity (Common Terminology Criteria for Adverse Events [CTCAE], version 3...
February 9, 2017: Clinical Oncology: a Journal of the Royal College of Radiologists
https://www.readbyqxmd.com/read/28188414/a-potential-panel-of-four-long-noncoding-rna-signature-in-prostate-cancer-predicts-biochemical-recurrence-free-survival-and-disease-free-survival
#11
Tian-Bao Huang, Chuan-Peng Dong, Guang-Chen Zhou, Sheng-Ming Lu, Yang Luan, Xiao Gu, Lei Liu, Xue-Fei Ding
PURPOSES: Growing evidences showed that lncRNAs abnormally expressed in cancer tissues and played irreplaceable roles in tumorigenesis, progression and metastasis. In present study, we aimed to identify lncRNA expression signature that can predict biochemical recurrence-free (BCR-free) survival of prostate cancer (PCa) patients. METHODS: A total of 291 patients with pathologic confirmed PCa in The Cancer Genome Atlas dataset were recruited and included. With the specific risk score formula, patients were further classified into high-risk group and low-risk group...
February 10, 2017: International Urology and Nephrology
https://www.readbyqxmd.com/read/28187996/pattern-of-solid-and-hematopoietic-second-malignancy-after-local-therapy-for-prostate-cancer
#12
Chenyang Wang, Christopher R King, Mitchell Kamrava, Keisuke S Iwamoto, Allen M Chen, Daniel Low, Patrick A Kupelian, Michael L Steinberg
BACKGROUND AND PURPOSE: Second malignancies (SM) after external beam radiotherapy (EBRT) or brachytherapy (BT) for prostate cancer (PCa) are rare but serious sequelae. MATERIALS AND METHODS: The Surveillance, Epidemiology, and End Results (SEER) database was used to identify men diagnosed with cT1-2N0M0 PCa between 1999 and 2005, who underwent EBRT, BT or radical prostatectomy (RP). Patients with time interval to second malignancy or follow-up shorter than five and two years were excluded for solid and hematopoietic SM analyses respectively...
February 7, 2017: Radiotherapy and Oncology: Journal of the European Society for Therapeutic Radiology and Oncology
https://www.readbyqxmd.com/read/28186846/in-vitro-mouse-and-human-serum-stability-of-a-heterobivalent-dual-target-probe-that-has-strong-affinity-to-gastrin-releasing-peptide-and-neuropeptide-y1-receptors-on-tumor-cells
#13
Arijit Ghosh, Natarajan Raju, Michael Tweedle, Krishan Kumar
Receptor-targeting radiolabeled molecular probes with high affinity and specificity are useful in studying and monitoring biological processes and responses. Dual- or multiple-targeting probes, using radiolabeled metal chelates conjugated to peptides, have potential advantages over single-targeting probes as they can recognize multiple targets leading to better sensitivity for imaging and radiotherapy when target heterogeneity is present. Two natural hormone peptide receptors, gastrin-releasing peptide (GRP) and Y1, are specifically interesting as their expression is upregulated in most breast and prostate cancers...
February 2017: Cancer Biotherapy & Radiopharmaceuticals
https://www.readbyqxmd.com/read/28185938/folate-targeted-nanoparticle-delivery-of-androgen-receptor-shrna-enhances-the-sensitivity-of-hormone-independent-prostate-cancer-to-radiotherapy
#14
Xinjun Zhang, Nianli Liu, ZhiYing Shao, Hui Qiu, Hong Yao, JiaYin Ji, Jianshe Wang, Wenchao Lu, Ronald C Chen, Longzhen Zhang
Androgen receptor (AR) plays a crucial role in the development and progression of prostate cancer (PCa). PCa patients typically receive androgen deprivation therapy; nonetheless, these patients eventually develop castration and radiation resistance. We hypothesized that we could further improve radiotherapeutic efficacy of hormone-independent PCa (HIPC) by silencing AR. In this study, nanoparticle (NP) AR-shRNA was formulated using folate-targeted H1 nanopolymer. We demonstrated that NP AR-shRNA enhances PCa radiosensitivity as indicated by the inhibition of cell growth, increased apoptosis, and increased cell cycle arrest in AR-dependent HIPC in vitro...
February 6, 2017: Nanomedicine: Nanotechnology, Biology, and Medicine
https://www.readbyqxmd.com/read/28185875/salvage-stereotactic-body-radiotherapy-for-isolated-lymph-node-recurrent-prostate-cancer-single-institution-series-of-94-consecutive-patients-and-124-lymph-nodes
#15
Barbara Alicja Jereczek-Fossa, Giuseppe Fanetti, Cristiana Fodor, Delia Ciardo, Luigi Santoro, Claudia Maria Francia, Matteo Muto, Alessia Surgo, Dario Zerini, Giulia Marvaso, Giorgia Timon, Paola Romanelli, Elena Rondi, Stefania Comi, Federica Cattani, Federica Golino, Stefano Mazza, Deliu Victor Matei, Matteo Ferro, Gennaro Musi, Franco Nolè, Ottavio de Cobelli, Piet Ost, Roberto Orecchia
BACKGROUND: The purpose of the study was to evaluate the prostate serum antigen (PSA) response, local control, progression-free survival (PFS), and toxicity of stereotactic body radiotherapy (SBRT) for lymph node (LN) oligorecurrent prostate cancer. PATIENTS AND METHODS: Between May 2012 and October 2015, 124 lesions were treated in 94 patients with a median dose of 24 Gy in 3 fractions. Seventy patients were treated for a single lesion and 25 for > 1 lesion...
January 11, 2017: Clinical Genitourinary Cancer
https://www.readbyqxmd.com/read/28185462/-options-of-chemotherapy-in-the-treatment-of-prostate-cancer
#16
I Richter, J Dvořák, J Bartoš
BACKGROUND: Prostate cancer is one of the most common malignancies in men. Chemotherapy has an important role in the management of prostate cancer, especially for the treatment of castrate resistant prostate cancer (mCRPC). According to recently published studies, chemotherapy can also be used to treat advanced hormone sensitive disease. AIM: The aim of this report is to review the currently available options for chemotherapy of prostate cancer. RESULTS: Docetaxel is a chemotherapeutic agent used for standard treatment of mCRPC as 1st line therapy...
2017: Klinická Onkologie: Casopis Ceské a Slovenské Onkologické Spolecnosti
https://www.readbyqxmd.com/read/28178275/phase-of-care-prevalence-for-prostate-cancer-in-new-south-wales-australia-a-population-based-modelling-study
#17
Xue Qin Yu, Qingwei Luo, David P Smith, Mark S Clements, Manish I Patel, Dianne L O'Connell
OBJECTIVE: To develop a method for estimating the future numbers of prostate cancer survivors requiring different levels of care. DESIGN, SETTING AND PARTICIPANTS: Analysis of population-based cancer registry data for prostate cancer cases (aged 18-84 years) diagnosed in 1996-2007, and a linked dataset with hospital admission data for men with prostate cancer diagnosed during 2005-2007 in New South Wales (NSW), Australia. METHODS: Cancer registry data (1996-2007) were used to project complete prostate cancer prevalence in NSW, Australia for 2008-2017, and treatment information from hospital records (2005-2007) was used to estimate the inpatient care needs during the first year after diagnosis...
2017: PloS One
https://www.readbyqxmd.com/read/28176411/diffusion-radiomics-analysis-of-intratumoral-heterogeneity-in-a-murine-prostate-cancer-model-following-radiotherapy-pixelwise-correlation-with-histology
#18
Yu-Chun Lin, Gigin Lin, Ji-Hong Hong, Yi-Ping Lin, Fang-Hsin Chen, Shu-Hang Ng, Chun-Chieh Wang
PURPOSE: To investigate the biological meaning of apparent diffusion coefficient (ADC) values in tumors following radiotherapy. MATERIALS AND METHODS: Five mice bearing TRAMP-C1 tumor were half-irradiated with a dose of 15 Gy. Diffusion-weighted images, using multiple b-values from 0 to 3000 s/mm(2) , were acquired at 7T on day 6. ADC values calculated by a two-point estimate and monoexponential fitting of signal decay were compared between the irradiated and nonirradiated regions of the tumor...
February 8, 2017: Journal of Magnetic Resonance Imaging: JMRI
https://www.readbyqxmd.com/read/28168601/long-term-follow-up-after-active-surveillance-or-curative-treatment-quality-of-life-outcomes-of-men-with-low-risk-prostate-cancer
#19
Lionne D F Venderbos, Shafak Aluwini, Monique J Roobol, Leonard P Bokhorst, Eric H G M Oomens, Chris H Bangma, Ida J Korfage
PURPOSE: To compare long-term (4-10 years) quality of life (QoL) of men with low-risk prostate cancer (PCa) treated by different modalities and a reference group without PCa. METHODS: In this cross-sectional study, four groups were sent a one-time QoL-questionnaire; PCa patients (1) following the structured Prostate cancer Research International Active Surveillance protocol, (2) who underwent radical prostatectomy (RP) in the context of the European Randomized study of Screening for Prostate Cancer-section Rotterdam, (3) who underwent radiotherapy (RT) at an academic hospital in The Netherlands, and (4) an age-matched reference group of men without PCa...
February 6, 2017: Quality of Life Research
https://www.readbyqxmd.com/read/28168138/racial-disparity-in-prostate-cancer-specific-mortality-for-high-risk-prostate-cancer-a-population-based-study
#20
Chenyang Wang, Mitchell Kamrava, Chris King, Michael L Steinberg
INTRODUCTION: Race may be a significant factor that influences prostate cancer (PCa) survival, with the Asian (AsA) race being associated with better outcomes compared to African American (AA) and Non-Hispanic Whites (NHW). This study evaluates race-dependent variation in PCa-specific mortality (PCSM) associated with radiation dose-escalation exemplified by external beam radiotherapy (EBRT) with a brachytherapy (BT) boost in Gleason score 8-10 PCa. METHODS: 28,956 men diagnosed with clinically localized PCa and Gleason score 8-10 from 2004-2013 who received EBRT, EBRT with a BT boost, or radical prostatectomy (RP) were identified using the Surveillance, Epidemiology, and End Results (SEER) database...
January 6, 2017: Curēus
keyword
keyword
64781
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"